Healthcare provider profile · identity verified

Maggie J King, MD

Family Practice · PRINEVILLE, OR · NPI 1457441586

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	437	117
Levothyroxine Sodium	Levothyroxine Sodium	306	73
Losartan Potassium	Losartan Potassium	306	76
Lisinopril	Lisinopril	266	79
Amlodipine Besylate	Amlodipine Besylate	249	69
Gabapentin	Gabapentin	182	61
Omeprazole	Omeprazole	179	45
Metoprolol Succinate	Metoprolol Succinate	177	47
Sertraline Hcl	Sertraline Hcl	169	38
Furosemide	Furosemide	152	42
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	142	33
Hydrochlorothiazide	Hydrochlorothiazide	137	36
Escitalopram Oxalate	Escitalopram Oxalate	133	33
Alendronate Sodium	Alendronate Sodium	130	38
Pantoprazole Sodium	Pantoprazole Sodium	130	43
Oxycodone Hcl	Oxycodone Hcl	123	25
Metformin Hcl	Metformin Hcl	116	30
Bupropion Xl	Bupropion Hcl	110	23
Tramadol Hcl	Tramadol Hcl	107	26
Eliquis	Apixaban	102	26
Tamsulosin Hcl	Tamsulosin Hcl	98	24
Albuterol Sulfate Hfa	Albuterol Sulfate	96	43
Rosuvastatin Calcium	Rosuvastatin Calcium	96	32
Lovastatin	Lovastatin	95	25
Lorazepam	Lorazepam	86	29
Trazodone Hcl	Trazodone Hcl	82	28
Fluoxetine Hcl	Fluoxetine Hcl	80	22
Duloxetine Hcl	Duloxetine Hcl	76	17
Ozempic	Semaglutide	75	13
Potassium Chloride	Potassium Chloride	71	28
Clonazepam	Clonazepam	68	15
Estradiol	Estradiol	65	18
Venlafaxine Hcl Er	Venlafaxine Hcl	63	14
Metoprolol Tartrate	Metoprolol Tartrate	59	16
Carvedilol	Carvedilol	56	14
Jardiance	Empagliflozin	56	11
Spironolactone	Spironolactone	56	15
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	54	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	52	14
Allopurinol	Allopurinol	51	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	51	suppressed
Methocarbamol	Methocarbamol	50	15
Buspirone Hcl	Buspirone Hcl	48	13
Prednisone	Prednisone	48	32
Clopidogrel	Clopidogrel Bisulfate	44	14
Montelukast Sodium	Montelukast Sodium	44	12
Rizatriptan	Rizatriptan Benzoate	44	suppressed
Tizanidine Hcl	Tizanidine Hcl	44	12
Trulicity	Dulaglutide	44	suppressed
Meloxicam	Meloxicam	43	11
Famotidine	Famotidine	40	12
Amitriptyline Hcl	Amitriptyline Hcl	38	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	38	11
Pregabalin	Pregabalin	38	11
Mounjaro	Tirzepatide	35	suppressed
Ezetimibe	Ezetimibe	34	13
Oxybutynin Chloride	Oxybutynin Chloride	32	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	32	suppressed
Propranolol Hcl	Propranolol Hcl	32	suppressed
Simvastatin	Simvastatin	32	suppressed
Mirtazapine	Mirtazapine	30	suppressed
Synthroid	Levothyroxine Sodium	28	suppressed
Comfort Ez Pen Needle	Pen Needle, Diabetic	26	suppressed
Ondansetron Odt	Ondansetron	26	suppressed
Glipizide	Glipizide	25	suppressed
Paroxetine Hcl	Paroxetine Hcl	25	suppressed
Metformin Hcl Er	Metformin Hcl	24	suppressed
Cephalexin	Cephalexin	23	19
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	23	suppressed
Solifenacin Succinate	Solifenacin Succinate	23	suppressed
Digoxin	Digoxin	22	suppressed
Atenolol	Atenolol	21	suppressed
Finasteride	Finasteride	20	suppressed
Glipizide Er	Glipizide	20	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	20	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	20	suppressed
Spiriva Handihaler	Tiotropium Bromide	20	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	20	suppressed
Fluticasone Propionate	Fluticasone Propionate	19	suppressed
Nystatin	Nystatin	19	14
Ondansetron Hcl	Ondansetron Hcl	19	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	19	16
Wixela Inhub	Fluticasone Propion/Salmeterol	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	18	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	18	suppressed
Xarelto	Rivaroxaban	18	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	17	suppressed
Telmisartan	Telmisartan	17	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	14
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Aripiprazole	Aripiprazole	15	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	15	suppressed
Promethazine Hcl	Promethazine Hcl	15	suppressed
Amiodarone Hcl	Amiodarone Hcl	14	suppressed
Clomipramine Hcl	Clomipramine Hcl	14	suppressed
Divalproex Sodium	Divalproex Sodium	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Levemir Flexpen	Insulin Detemir	14	suppressed
Pravastatin Sodium	Pravastatin Sodium	14	suppressed
Donepezil Hcl	Donepezil Hcl	13	suppressed
Loperamide	Loperamide Hcl	13	suppressed
Meclizine Hcl	Meclizine Hcl	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	12	suppressed
Topiramate	Topiramate	12	suppressed
Triazolam	Triazolam	12	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Buprenorphine	Buprenorphine	11	suppressed
Carisoprodol	Carisoprodol	11	suppressed
Diclofenac Sodium	Diclofenac Sodium	11	suppressed
Gemfibrozil	Gemfibrozil	11	suppressed
Insulin Aspart Flexpen	Insulin Aspart	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error